Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study

Srinivasan, Ramaprasad, Iliopoulos, Othon, Beckermann, Kathryn E · The Lancet Oncology · 2025